Intact provides software solutions for the audit, assessment, certification, accreditation, and standards management sectors. The platform is designed to enhance efficiency and transparency in these areas.

Intact

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Paul DeRidder

CG Oncology, Inc. Common stock

Embroker is an insurance company that leverages technology to streamline the process of obtaining and managing insurance for businesses. It offers a digital platform for comparing, purchasing, and managing insurance policies, aiming to simplify the traditionally complex and time-consuming tasks associated with business insurance.

Matt Miller

Yotam Shacham

Embroker

Infinite Ireland Travel Co. offers travel planning services for trips to Ireland, focusing on handcrafted itineraries that cater to local experiences and accommodations. The company provides logistical support and manages travel arrangements.

Metric
Company Name	Intact	CG Oncology, Inc. Common stock	Embroker	Infinite Ireland Travel Co.
Symbol		CGON
MSH ID	COM:INTACT-SYSTEMS	COM:CGONCOLOGY	COM:EMBROKER	COM:INFINITEIRELAND
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Technology	Healthcare	Financial Services & Finance	Consumer Services
Industry	Software and Services	Biotechnology	Insurance	Travel & Tourism
Country	DE		US	IE
Stage
Employee Count		61	192
Website	intact-systems.com		embroker.com	infiniteireland.com
LinkedIn		cgoncology	embroker
Founders

Metric
Market Cap		2.19B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		204K
Revenue (LTM)
Revenue (NTM)
Gross Profit		187K
EBITDA		-55.43M
Operating Income		-55.45M
Net Income		-48.61M
EPS		-0.73
Diluted EPS		-0.73
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.98
Operating Profit Margin		-70.61
EBITDA Margin		-271.73
Net Profit Margin		-57.62
Return on Equity		-0.21
Return on Assets		-0.07
Return on Capital Employed		-0.09

COM:INTACT-SYSTEMS

Intact

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-37.50
P/B Ratio		2.75
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		4.07K
EV Multiple		-27.87

Metric
Days Sales Outstanding		77.13
Days Payables Outstanding		216.58
Days Inventory Outstanding
Operating Cycle		103.63
Cash Conversion Cycle		-139.45
Asset Turnover		0.00

Metric
Operating Cash Flow		-45.68M
Free Cash Flow		-45.68M
Cash Flow to Debt		-123.91
Operating Cash Flow/Sales		-69.14
Free Cash Flow Yield		-0.02

Metric
Cash & Equivalents		8.27M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization		0.00
Debt to Assets		0.00
Current Ratio		57.95
Quick Ratio		57.95

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		3.42
R&D to Revenue		56.58
SG&A to Revenue		15.03